Evropska unija - slovenščina - EMA (European Medicines Agency)

bavarian nordic a/s - vibrio cholerae, sev cvd 103-hgr, v živo - kolera - cepiva - vaxchora is indicated for active immunisation against disease caused by vibrio cholerae serogroup o1 in adults and children aged 2 years and older. to cepivo je treba uporabljati v skladu z uradnimi priporočili.

Evropska unija - slovenščina - EMA (European Medicines Agency)

valneva sweden ab - rekombinantne kolera toksin b podenote, vibrio cholerae 01 - cholera; immunization - cepiva - zdravilo dukoral je indicirano za aktivno imunizacijo proti bolezni, ki jo povzroča serotip skupine vibrio cholerae o1 pri odraslih in otrocih, starih od 2 let, ki bodo obiskali endemične / epidemične površine. uporaba dukoral je treba določiti na podlagi uradnih priporočil, ob upoštevanju variabilnosti epidemiologija in tveganje stranke bolezni v različnih geografskih področjih in potujejo pogoji. dukoral ne sme nadomestiti standardne zaščitne ukrepe. v primeru driske ukrepov za rehidracijo, je treba začeti.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

ceva santé animale 10 avenue de la ballastière 33500 libourne francija proizvajalec odgovoren za sproščanje serij: ceva santé animale 10 -

Evropska unija - slovenščina - EMA (European Medicines Agency)

biogen netherlands b.v. - natalizumab - multiple skleroza - selektivni imunosupresivi - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 in 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Evropska unija - slovenščina - EMA (European Medicines Agency)

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresivi - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 in 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

ceva sante animale -

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

ceva santé animale -

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

ceva santé animale -

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

ceva santé animale -

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

ceva sante animale 10 av -